Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Preston Purdum

Gastroenterology Charlotte, NC Medical Doctor

NPI 1275566283 CMS profile 11944

300 Billingsley Rd Ste 200, Charlotte, NC 28211

Open in the dashboard

General payments

$9,449

611 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Preston Purdum of Charlotte, NC is reported in the CMS Open Payments database as having received $9,449 across 611 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,778 102
2021 General $3,512 232
2020 General $2,162 138
2019 General $1,997 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Preston Purdum
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Preston Purdum were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Preston Purdum Gastroenterology median Middle half National median
2019 $1,997 $417 $126–$1,100 $163
2020 $2,162 $224 $74–$624 $114
2021 $3,512 $352 $106–$1,054 $132
2022 $1,778 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $1,990 117 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,210 83 payments
  3. Janssen Biotech, Inc. $996 68 payments
  4. Gilead Sciences, Inc. $883 65 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $859 59 payments
  6. Ferring Pharmaceuticals Inc. $308 18 payments
  7. Celgene Corporation $298 23 payments
  8. Alnylam Pharmaceuticals Inc. $289 17 payments
  9. QOL Medical, LLC $287 22 payments
  10. Intercept Pharmaceuticals, Inc. $264 17 payments
  11. Other $2,067 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $9,441 610 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2022
  1. STELARA $1,020 69 payments
  2. HUMIRA $1,013 56 payments
  3. XIFAXAN $551 37 payments
  4. ENTYVIO Internal Medicine $473 27 payments
  5. ZEPOSIA $413 24 payments
  6. CREON $388 27 payments
  7. MAVYRET $386 24 payments
  8. Entyvio Lower GI $319 22 payments
  9. GIVLAARI $289 17 payments
  10. Sucraid $287 22 payments
  11. Other $4,191 262 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

18

Median for Internal Medicine: 777

Drug cost

$264

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Famotidine Generic 18 $264

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

611 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record